306 related articles for article (PubMed ID: 34095878)
21. DNA repair defects and implications for immunotherapy.
Bever KM; Le DT
J Clin Invest; 2018 Oct; 128(10):4236-4242. PubMed ID: 30272580
[TBL] [Abstract][Full Text] [Related]
22. Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers.
Cerniglia M; Xiu J; Grothey A; Pishvaian MJ; Baca Y; Hwang JJ; Marshall JL; VanderWalde AM; Shields AF; Lenz HJ; Korn WM; Salem M; Philip PA; Goldberg RM; Zeng J; Kim SS
Mol Cancer Ther; 2022 Jan; 21(1):227-236. PubMed ID: 34725190
[TBL] [Abstract][Full Text] [Related]
23.
Li M; Ma Y; Zhong Y; Liu Q; Chen C; Qiang L; Wang X
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037113
[TBL] [Abstract][Full Text] [Related]
24. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer.
Ma J; Setton J; Lee NY; Riaz N; Powell SN
Nat Commun; 2018 Aug; 9(1):3292. PubMed ID: 30120226
[TBL] [Abstract][Full Text] [Related]
25. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Acta Pharm Sin B; 2021 Oct; 11(10):2983-2994. PubMed ID: 34729299
[TBL] [Abstract][Full Text] [Related]
26. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
[TBL] [Abstract][Full Text] [Related]
27. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
28. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
29. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
Aktas BY; Guner G; Guven DC; Arslan C; Dizdar O
Expert Rev Anticancer Ther; 2019 Jul; 19(7):589-601. PubMed ID: 31181965
[No Abstract] [Full Text] [Related]
30. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.
Arjumand W; Asiaf A; Ahmad ST
Methods Mol Biol; 2018; 1699():3-21. PubMed ID: 29086365
[TBL] [Abstract][Full Text] [Related]
31. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.
Viale G; Trapani D; Curigliano G
Biomed Res Int; 2017; 2017():4719194. PubMed ID: 28770222
[TBL] [Abstract][Full Text] [Related]
32. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
[TBL] [Abstract][Full Text] [Related]
33. A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer.
Ding K; He Y; Wei J; Fu S; Wang J; Chen Z; Zhang H; Qu Y; Liang K; Gong X; Qiu L; Chen D; Xiao B; Du H
Front Immunol; 2022; 13():943090. PubMed ID: 36081518
[TBL] [Abstract][Full Text] [Related]
34. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
35. Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.
Wang Z; Zhao J; Wang G; Zhang F; Zhang Z; Zhang F; Zhang Y; Dong H; Zhao X; Duan J; Bai H; Tian Y; Wan R; Han M; Cao Y; Xiong L; Liu L; Wang S; Cai S; Mok TSK; Wang J
Cancer Res; 2018 Nov; 78(22):6486-6496. PubMed ID: 30171052
[TBL] [Abstract][Full Text] [Related]
36. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
Zhou C; Lin A; Cao M; Ding W; Mou W; Guo N; Chen Z; Zhang J; Luo P
Front Immunol; 2021; 12():634741. PubMed ID: 34220801
[TBL] [Abstract][Full Text] [Related]
37. DNA damage response pathways in tumor suppression and cancer treatment.
Liang Y; Lin SY; Brunicardi FC; Goss J; Li K
World J Surg; 2009 Apr; 33(4):661-6. PubMed ID: 19034564
[TBL] [Abstract][Full Text] [Related]
38. Interfaces between cellular responses to DNA damage and cancer immunotherapy.
Pilger D; Seymour LW; Jackson SP
Genes Dev; 2021 May; 35(9-10):602-618. PubMed ID: 33888558
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors.
Rochefort P; Desseigne F; Bonadona V; Dussart S; Coutzac C; Sarabi M; la Fouchardiere C
Immunotherapy; 2021 Oct; 13(14):1205-1213. PubMed ID: 34494466
[TBL] [Abstract][Full Text] [Related]
40. Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy.
Czajkowski D; Szmyd R; Gee HE
J Med Imaging Radiat Oncol; 2022 Jun; 66(4):546-559. PubMed ID: 35460184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
